Boston Scientific announced withSoniVieThe final acquisition agreement was signed, with acquisition costs as high as 600 million US dollars (including a 400 million US dollar upfront payment and a 200 million US dollar milestone bonus). However, Boston Scientific currently holdsSoniVie 10%Therefore, Boston Scientific will ultimately only need to pay 540 million US dollars.Boston Scientific Through AcquisitionSoniVieReturn to RD AgainN Family."For millions of patients, renal denervation to treat hypertension is an exciting medical advancement that may offer help and is supported by positive outcomes from contemporary clinical trials and ongoing research. We believe that adding the differentiated TIVUS ablation technology based on ultrasound can complement our broad portfolio of interventional treatments, providing minimally invasive options for patients with hypertension and offering opportunities for future development in this field."---Lance Bates Senior Vice President and President of Interventional Cardiology at Boston ScientificRDN (Renal Denervation) is a minimally invasive interventional procedure for the non-pharmacological treatment of hypertension, using radiofrequency energy or other physical methods.The method involves ablating sympathetic nerves on the outer membrane of the renal artery to reduce blood pressure. Currently, the FDA has approved two RDN products for marketing (Medtronic's...Symplicity SpyralAndReCor MedicalTheParadise）, and receive CMS Medicare payment support. Due to the large population of hypertension patients, obvious efficacy of RDN, and the support of medical insurance, RDN has become one of the fastest-growing segments in the medical device field in the next five years, according toLSI Prediction:From 2023 to 2028,RDNThe market's compound annual growth rate will reach 22.0%.。2022TIVUSReceived FDA approval for IDE clinical trials and completed clinical enrollment in early last year, indicatingTIVUS Nears FDA Approval for Market Launch; Boston Scientific Makes Strategic AcquisitionSoniVie, allowing Boston Scientific to have an opportunity in the yet-unshaped RDN market landscape, competing against Medtronic andReCor Medical has seized a large enough market share and even has the opportunity to surpass Medtronic.
After all, radiofrequency ablation in the year FThe Cardiovascular Subcommittee of the DA Medical Advisory Committee voted against it.TIVUSAs an ultrasound-based RND technology, it does not need to contact the blood vessel wall compared with Paradise, avoiding blood vessel injury (which may cause subsequent blood vessel stenosis, and stenosis is also a cause of hypertension).
Before 2014, Boston Scientific was also one of the major global participants in RDN. However, after Medtronic announced the clinical study showing RDN to be ineffective for treating hypertension, Boston Scientific chose to exit. Instead of investing substantial resources into a project with an uncertain future, they waited until RDN received FDA approval. Boston Scientific then re-entered the RDN field at a price of less than $600 million (while Medtronic had spent $800 million to acquire Ardian back in the day), demonstrating Boston Scientific's shrewdness.
Through this acquisition, Boston Scientific not only gains the RDN product but also obtains two additional products: pulmonary artery hypertension denervation and chronic obstructive pulmonary disease with chronic bronchitis denervation.
TIVUS(Therapeutic Intravascular Ultrasound) isA catheter-based endovascular technique for renal and bronchial denervationPeripheral Sympathetic Nerves。TIVUSTheThe distal end of the catheter can generate non-focused ultrasound waves, which can penetrate through flowing blood and arterial walls. The energy in the vascular wall is absorbed by the tissue outside the vessel (especially nerve bundles). This leads to nerve heating, causing sympathetic nerve death, thus...Sympathetic NerveLoss of its ability to transmit signals. This leads to a reduction in the release of sympathetic hormones from nerves. The decrease in these hormones can cause blood vessels to relax, reducing vascular resistance, vascular pressure, and pulmonary hypertension, as well as decreasing resistance on the right side of the heart.
TIVUS Demonstration
SoniVie
SoniVieIn 2014 by Accelled Ventures in IsraelEstablished,Is a developmentTIVUSMedical device companies,TIVUSIs the only ultrasound denervation platform with active development programs in three therapeutic areas: pulmonary artery hypertension denervation, renal artery denervation for resistant hypertension, and denervation for chronic obstructive pulmonary disease with chronic bronchitis. These conditions affect millions of patients in the United States and Europe.
